tiprankstipranks
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
US Market
CRBP
Corbus Pharmaceuticals
RESEARCH TOOLSreports
Want to see CRBP full AI Analyst Report?

Corbus Pharmaceuticals (CRBP) Stock Forecast & Price Target

2,588 Followers
See the Price Targets and Ratings of:

CRBP Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Corbus
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRBP Stock 12 Month Forecast

Average Price Target

$38.67
▲(265.12% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $38.67 with a high forecast of $54.00 and a low forecast of $28.00. The average price target represents a 265.12% change from the last price of $10.59.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","55":"$55","18.25":"$18.25","30.5":"$30.5","42.75":"$42.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18.25,30.5,42.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.75,11.307692307692307,14.865384615384615,18.423076923076923,21.98076923076923,25.538461538461537,29.096153846153847,32.65384615384615,36.21153846153846,39.76923076923077,43.32692307692307,46.88461538461538,50.44230769230769,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.75,10.128205128205128,12.506410256410255,14.884615384615385,17.26282051282051,19.641025641025642,22.01923076923077,24.397435897435898,26.775641025641026,29.153846153846153,31.53205128205128,33.91025641025641,36.28846153846154,{"y":38.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.75,9.307692307692308,10.865384615384615,12.423076923076923,13.98076923076923,15.538461538461538,17.096153846153847,18.653846153846153,20.21153846153846,21.76923076923077,23.326923076923077,24.884615384615383,26.442307692307693,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$54.00Average Price Target$38.67Lowest Price Target$28.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRBP
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
277.71%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Mirum Pharmaceuticals (NASDAQ: MIRM) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Oppenheimer Analyst forecast on CRBP
Leland Gershell
Oppenheimer
Oppenheimer
$54
Buy
409.92%
Upside
Reiterated
06/02/26
Oppenheimer Remains a Buy on Corbus Pharmaceuticals (CRBP)
Guggenheim Analyst forecast on CRBP
Paul Jeng
Guggenheim
Guggenheim
$45
Buy
324.93%
Upside
Reiterated
06/02/26
Corbus Pharmaceuticals (CRBP) Gets a Buy from Guggenheim
William Blair Analyst forecast on CRBP
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
06/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (NASDAQ: JSPR) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Mizuho Securities Analyst forecast on CRBP
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$44
Buy
315.49%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP)
Wedbush Analyst forecast on CRBP
Robert Driscoll
Wedbush
Wedbush
$38→$30
Buy
183.29%
Upside
Reiterated
05/27/26
Wedbush Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)
LifeSci Capital Analyst forecast on CRBP
Oliver McCammon
LifeSci Capital
LifeSci Capital
$38
Buy
258.83%
Upside
Reiterated
05/26/26
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
RBC Capital Analyst forecast on CRBP
Brian Abrahams
RBC Capital
RBC Capital
$51→$36
Buy
239.94%
Upside
Reiterated
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Jefferies Analyst forecast on CRBP
Maury Raycroft
Jefferies
Jefferies
$36→$33
Buy
211.61%
Upside
Reiterated
05/12/26
Corbus Pharmaceuticals price target lowered to $33 from $36 at JefferiesCorbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
B. Riley Securities Analyst forecast on CRBP
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
$28
Buy
164.40%
Upside
Reiterated
04/10/26
We reiterate our buy ratings on CRBP ($28 PT)
Piper Sandler Analyst forecast on CRBP
Biren Amin
Piper Sandler
Piper Sandler
$35→$51
Buy
381.59%
Upside
Reiterated
10/20/25
Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRBP
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
277.71%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Mirum Pharmaceuticals (NASDAQ: MIRM) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Oppenheimer Analyst forecast on CRBP
Leland Gershell
Oppenheimer
Oppenheimer
$54
Buy
409.92%
Upside
Reiterated
06/02/26
Oppenheimer Remains a Buy on Corbus Pharmaceuticals (CRBP)
Guggenheim Analyst forecast on CRBP
Paul Jeng
Guggenheim
Guggenheim
$45
Buy
324.93%
Upside
Reiterated
06/02/26
Corbus Pharmaceuticals (CRBP) Gets a Buy from Guggenheim
William Blair Analyst forecast on CRBP
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
06/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (NASDAQ: JSPR) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Mizuho Securities Analyst forecast on CRBP
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$44
Buy
315.49%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP)
Wedbush Analyst forecast on CRBP
Robert Driscoll
Wedbush
Wedbush
$38→$30
Buy
183.29%
Upside
Reiterated
05/27/26
Wedbush Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)
LifeSci Capital Analyst forecast on CRBP
Oliver McCammon
LifeSci Capital
LifeSci Capital
$38
Buy
258.83%
Upside
Reiterated
05/26/26
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
RBC Capital Analyst forecast on CRBP
Brian Abrahams
RBC Capital
RBC Capital
$51→$36
Buy
239.94%
Upside
Reiterated
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Jefferies Analyst forecast on CRBP
Maury Raycroft
Jefferies
Jefferies
$36→$33
Buy
211.61%
Upside
Reiterated
05/12/26
Corbus Pharmaceuticals price target lowered to $33 from $36 at JefferiesCorbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
B. Riley Securities Analyst forecast on CRBP
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
$28
Buy
164.40%
Upside
Reiterated
04/10/26
We reiterate our buy ratings on CRBP ($28 PT)
Piper Sandler Analyst forecast on CRBP
Biren Amin
Piper Sandler
Piper Sandler
$35→$51
Buy
381.59%
Upside
Reiterated
10/20/25
Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corbus Pharmaceuticals

3 Months
Andy HsiehWilliam Blair
Success Rate
6/11 ratings generated profit
55%
Average Return
-2.79%
Copying Andy Hsieh's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of -2.79% per trade.
1 Year
Andy HsiehWilliam Blair
Success Rate
4/11 ratings generated profit
36%
Average Return
-1.96%
Copying Andy Hsieh's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -1.96% per trade.
2 Years
Andy HsiehWilliam Blair
Success Rate
4/11 ratings generated profit
36%
Average Return
-10.09%
Copying Andy Hsieh's trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of -10.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRBP Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
6
6
13
26
24
Buy
1
1
2
4
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
15
30
28
In the current month, CRBP has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRBP average Analyst price target in the past 3 months is 38.67.
Each month's total comprises the sum of three months' worth of ratings.

CRBP Financial Forecast

CRBP Earnings Forecast

Next quarter’s earnings estimate for CRBP is -$1.26 with a range of -$1.38 to -$1.15. The previous quarter’s EPS was -$1.23. CRBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CRBP has Performed in-line its overall industry.
Next quarter’s earnings estimate for CRBP is -$1.26 with a range of -$1.38 to -$1.15. The previous quarter’s EPS was -$1.23. CRBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CRBP has Performed in-line its overall industry.

CRBP Sales Forecast

Next quarter’s sales forecast for CRBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CRBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CRBP has Performed in-line its overall industry.
Next quarter’s sales forecast for CRBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CRBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CRBP has Performed in-line its overall industry.

CRBP Stock Forecast FAQ

What is CRBP’s average 12-month price target, according to analysts?
Based on analyst ratings, Corbus Pharmaceuticals’s 12-month average price target is 38.67.
    What is CRBP’s upside potential, based on the analysts’ average price target?
    Corbus Pharmaceuticals has 265.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRBP a Buy, Sell or Hold?
          Corbus Pharmaceuticals has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Corbus Pharmaceuticals’s price target?
            The average price target for Corbus Pharmaceuticals is 38.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $54.00 ,the lowest forecast is $28.00. The average price target represents 265.12% Increase from the current price of $10.59.
              What do analysts say about Corbus Pharmaceuticals?
              Corbus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of CRBP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.